HITLAB Debuts HealthTech Launchpad USA, a New Commercialization Engine for Global Health Innovators
New York, NY — July 17, 2026 — HITLAB, the health innovation and technology organization, today announced the launch of HealthTech Launchpad USA, a new commercialization program designed to help healthcare and life sciences innovators — particularly those outside the U.S. — translate strong technology into real traction in the American market.
For more than 25 years, HITLAB has made health technologies U.S.-ready, building the clinical and economic evidence that stands up to the scrutiny of U.S. payers, providers, and regulators. HealthTech Launchpad USA turns that experience into a structured program: a five-part pathway spanning commercialization strategy, clinical validation, strategic partnerships, investment readiness, and U.S. market entry.
Healthcare adoption requires more than a compelling product. Through the program, participants learn to map the stakeholders, buyers, and care settings that determine adoption; identify the coding, coverage, and payment routes that make the economics work for U.S. payers; and navigate FDA and CMS regulatory pathways at each milestone. From there, HITLAB helps companies build relationships with U.S. pilot sites and health systems, lead IRB-approved pilot studies with clinical-research rigor, and align to U.S. customer expectations to drive adoption across the health system.
The program is built for a wide range of innovators — digital health startups, AI and analytics companies, medtech and device makers, biotech and therapeutics platforms, academic spinouts, and international companies seeking their first foothold in the U.S. Each cohort works from HITLAB’s New York City base, positioning participants at the center of one of the world’s most active healthcare, life sciences, and investment ecosystems.
“Great technology isn’t enough on its own — it has to prove itself against the standards U.S. payers, providers, and regulators actually use,” said Dr. Stan Kachnowski, Chair of HITLAB. “That’s the gap HealthTech Launchpad USA is built to close. We’ve spent 25 years learning what it takes for an innovation to earn its place in American healthcare, and now we’re putting that road map directly in the hands of the founders who need it.”
HealthTech Launchpad USA is now accepting applications for its next cohort, along with partnership and sponsorship opportunities for health systems, pharma, payers, employers, investors, and technology companies.
Learn More about
About HealthTech Launchpad USA
HealthTech Launchpad USA is HITLAB’s commercialization engine for healthcare and life sciences innovators seeking U.S. traction — a five-part parallel acceleration pathway covering commercialization strategy, clinical validation, strategic partnerships, investment readiness, and U.S. market entry, backed by more than 650 validation studies conducted over 20+ years from HITLAB’s New York City base.
About HITLAB
For more than 25 years, HITLAB has been an independent research and evidence organization that prepares health technologies for the U.S. market. HITLAB’s rigorous clinical and economic research, combined with its communications and industry networks, helps innovators unlock new partnerships, funding, and market access — advancing a single mission: bringing breakthrough technology into U.S. care to improve the lives of 350 million Americans.
Share the article:
